PharmD, Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center
Dr Howard McLeod is chair of the Department of Individualized Cancer Management and a State of Florida Cancer Research Endowed Chair. He is a Professor at the University of South Florida and a 1000 Talent Scholar of China. Dr McLeod is a recent member of the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council. Dr McLeod is vice chair for Pharmacogenomics for NCI ALLIANCE clinical trials group, overseeing the largest oncology pharmacogenomics portfolio in the world. Dr McLeod is an active entrepreneur, serving on the Board of Directors, Scientific Advisory Board, and as a domain expert consultant to publically traded and privately held companies. He has also founded both for-profit and non- profit companies in the USA and China. Howard has published over 500 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance individualized medicine.
Session Synopsis: Precision Medicine (PM) leaders will discuss issues and lessons learned implementing PM programs as well as opportunities for community oncology practices. Topics include: requirements for creating a precision medicine program (personnel, supports; working with sequencing labs;interpreting results;and tools needed to scale and bring genomic-guided therapies to physicians and patients). A presentation of the PrecisionPlan™ oncology workbench to facilitate patient-specific genomic-guided treatment plans at point-of-care in real-time will support the discussion.